ClinicalTrials.gg
RecruitingNCT07393659PATHUpdated Nov 13, 2026

A Continued Access Study for Participants Transitioning From ViiV Healthcare-sponsored or ViiV Healthcare-collaborative Parent Studies for HIV Treatment

A Phase 3 interventional study of Fostemsavir and Dolutegravir (DTG)/ Lamivudine (3TC) in HIV Infections, sponsored by ViiV Healthcare. Recruiting at 9 sites in 3 countries. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2026; still recruiting 3 months later.
Updated Nov 13, 2026First sites in Romania and UgandaEnrollment updated+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
197
Allocation
Not applicable
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 55 studies testing dolutegravir in HIV Infections — 7 open to participants now, 9 under way, 4 of them phase 3. Dolutegravir · HIV Infections.

Planned enrollment
18th of 55
197 · median 126
Started
2026
with 1 other
Phase 3
21 of 55
2 open now
Registered
54th of 55
by date
Lead sponsor
26 of 55
ViiV Healthcare

Among the 55 studies testing dolutegravir in HIV Infections, this one is the 18th largest by planned enrollment, is one of 2 that started in 2026, is one of 21 in phase 3, and was the 54th registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

7 of the 55 studies testing dolutegravir in HIV Infections are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About dolutegravir

Dolutegravir: first FDA approval 2013 (TIVICAY), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 55 studies testing dolutegravir in HIV Infections, or all of them as a file.
02

Study summary

The purpose of this study is to provide continued access to the study treatment for participants from previous ViiV Healthcare studies who are still benefiting from it and do not have local access after completing the parent study. This continued access will also allow further collection of safety data. Eligible participants are those who completed a ViiV Healthcare-sponsored or collaborative parent study and are currently experiencing clinical benefit. The Sponsor will periodically review the study to consider other treatment access options.

03

Conditions studied

  • HIV Infections

Keywords

  • Human Immunodeficiency Virus (HIV)
  • Open label
  • Continued access
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Investigator confirmation of the participant's continued clinical benefit from the parent study intervention and the participant's completion of the protocol-defined treatment period in the parent study. The Investigator should ensure that the participant is still eligible for the parent study (i.e., have not met parent study discontinuation/ withdrawal criteria).
  • Participants or legally authorized representative (LAR) who are willing and able to comply with all scheduled visits, treatment plan, and other study procedures as outlined in the applicable appendix and determined by the Investigator.
  • Participant or LAR is able and willing to provide signed , which includes compliance with the requirements and restrictions listed in the consent form and this protocol. Where applicable, participants must provide written assent.

Exclusion criteria

Exclusion Criteria:

  • Any reason that, in the opinion of the Investigator or Sponsor, precludes the participant's inclusion in the study.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
197 participants (estimated)

Study arms

  • Experimental
    Continued Access Group

    Participants with HIV-1 who received the study intervention and completed the protocol-defined treatment period in ViiV Healthcare-sponsored or ViiV Healthcare-collaborative parent studies (2020-001029-30, 2020-001426-57), and who continue to receive the study intervention from their respective parent study.

    Drug: Fostemsavir · Drug: Dolutegravir (DTG)/ Lamivudine (3TC)

Interventions

  • Participants receive oral tablets with the dosages depending on the weight of the participants.

  • DrugDolutegravir (DTG)/ Lamivudine (3TC)

    Drug pages: Dolutegravir · Lamivudine

    Participants receive oral tablets with the dosages depending on the weight of the participants.

06

What researchers measure

Primary outcomes

  1. Number of participants who discontinue the study intervention and the reason for discontinuation

    Time frame: Throughout the study period (from rollover visit at Day 1 until the end of study/withdrawal visit)

  2. Number of participants with serious adverse events (SAE)

    A SAE is defined as any untoward medical occurrence that, at any dose, results in results in death, is life- threatening, requires inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant, abnormal pregnancy outcomes or a suspected transmission of any infectious agent via an authorized medicinal product.

    Time frame: Throughout the study period (from rollover visit at Day 1 until the end of study /withdrawal visit)

  3. Number of participants with adverse events of special interest (AESI)

    An adverse event (AE) is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AESI is defined as an AE of a scientific and medical concern specific to the study intervention, which may require further investigation in order to characterize and understand it.

    Time frame: Throughout the study period (from rollover visit at Day 1 until the end of study /withdrawal visit)

07

Study locations

9 of 9 sites recruiting
  • GSK Investigational Site
    Bucharest, 021105, Romania
    Recruiting
  • GSK Investigational Site
    Durban, KwaZulu-Natal 4013, South Africa
    Recruiting
  • GSK Investigational Site
    Jouberton, Matlosana 2571, South Africa
    Recruiting
  • GSK Investigational Site
    Gauteng, 1864, South Africa
    Recruiting
  • GSK Investigational Site
    Johannesburg, 2001, South Africa
    Recruiting
  • GSK Investigational Site
    Johannesburg, 2112, South Africa
    Recruiting
  • GSK Investigational Site
    Kampala, 10005, Uganda
    Recruiting
  • GSK Investigational Site
    Kampala, 759125, Uganda
    Recruiting
  • GSK Investigational Site
    Kampala, Uganda
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Study sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.viiv-studyregister.com/documents/About_ViiV_Patient_Level_Data_Sharing_Final_25Sep2023.pdf.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or asset(s) with development terminated across all indications.

Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension may be granted, when justified, for up to 6 months.

Data sharing details ↗ · www.viiv-studyregister.com

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Sep 2032, 73 months after the start.

Of 57 industry-sponsored phase 3 interventional studies under HIV Infections, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 30. This study's planned 73 months is above that.

Counting every sponsor, half of 101 studies reached it within 27 months; a quarter within 20 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 30, 2026
First posted
Feb 6, 2026
StartActual
Jul 21, 2026
Primary completionEst.
Sep 14, 2032
CompletionEst.
Sep 14, 2032
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
5 sites added — first sites in Romania and Uganda
Show 5 added (3 Uganda, 1 Romania, 1 South Africa)
  • GSK Investigational Site · Bucharest, Romania
  • GSK Investigational Site · Johannesburg, South Africa
  • GSK Investigational Site · Kampala, Uganda
  • GSK Investigational Site · Kampala, Uganda
  • GSK Investigational Site · Kampala, Uganda
Nov 13, 2026
Enrollment
181→197
Nov 13, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • GSK Investigational Site · Johannesburg, South AfricaContact person changed (no phone or email listed)
Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    5 sites added — first sites in Romania and Uganda
    Show 5 added (3 Uganda, 1 Romania, 1 South Africa)
    • GSK Investigational Site · Bucharest, Romania
    • GSK Investigational Site · Johannesburg, South Africa
    • GSK Investigational Site · Kampala, Uganda
    • GSK Investigational Site · Kampala, Uganda
    • GSK Investigational Site · Kampala, Uganda
    Enrollment 181→197
    Site contacts Changed at 1 site. See the sites
    Show the site
    • GSK Investigational Site · Johannesburg, South AfricaContact person changed (no phone or email listed)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07393659
Lead sponsor
ViiV Healthcare
Responsible party
Sponsor
First posted
Feb 6, 2026
Start date
Jul 21, 2026
Primary completion
Sep 14, 2032 (estimated)
Completion
Sep 14, 2032 (estimated)
Last update
Nov 13, 2026

Study contacts

US GSK Clinical Trials Call Center
Contact
GSKClinicalSupportHD@gsk.com
877-379-3718
EU GSK Clinical Trials Call Center
Contact
GSKClinicalSupportHD@gsk.com
+44 (0) 20 89904466

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Fostemsavir · Dolutegravir · Lamivudine

Start the discussion